-
Henan Province Sees 53.6% Price Reduction in Neuro and Peripheral Intervention Consumables Tender
•
The Henan Province Public Resources Trading Center has released a notification regarding the completion of price negotiations for neural intervention and peripheral intervention high-value consumable products as part of a consumables alliance procurement tender. The tender, which covered 2,323 specifications, resulted in an average price reduction of 53.6%. Led by…
-
Jiangsu Hillgene Biopharma Secures Tens of Millions in Series A Financing for Cell Therapy R&D
•
China-based cell therapy-focused Contract Development and Manufacturing Organization (CDMO) Jiangsu Hillgene Biopharma Co., Ltd has reportedly raised tens of millions of renminbi in a Series A financing round. The funding round was led by Jiarui Investment and Hesheng Venture Capital. The proceeds from this investment will be directed towards the…
-
Forecyte Bio Expands with New Cell and Gene Therapy GMP Facility in Shanghai
•
Maryland-based Contract Development and Manufacturing Organization (CDMO) Forecyte Biotechnologies has announced the opening of a new, state-of-the-art cell and gene therapy (CGT) GMP facility in Shanghai on March 31. This marks the company’s second facility, following the opening of a US-based facility in January. Investment and Global Impact of the…
-
Yiling Pharmaceutical’s XY0206 Advances to Phase III Trial for FLT3-ITD AML
•
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced its plans to initiate a Phase III clinical study for its Category 1 chemical drug XY0206, which targets recurrent/refractory acute myeloid leukemia (AML) patients with FLT3-ITD mutation (FMS-like tyrosine kinase 3 internal tandem duplication). XY0206: A Promising Multi-Target Tyrosine Kinase InhibitorXY0206…
-
Jiangsu Yuyue Medical Secures NMPA Approval for Semi-Automatic External Defibrillator
•
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (SHE: 002223), a China-based medical device company, has announced that it has received medical device marketing approval from the National Medical Products Administration (NMPA) for its semi-automatic external defibrillator (AED). Innovative Features of the AED ProductThe newly approved AED comes equipped with…
-
MicuRx Pharmaceuticals Initiates Phase III Study for MRX-4 in Diabetic Foot Infection Treatment
•
Sino-US firm MicuRx Pharmaceuticals Inc. has announced the initiation of a Phase III clinical study for its novel anti-microbial agent MRX-4, used in combination with contezolid (MRX-I), as a sequential treatment for diabetic foot infection in China. Global Multi-Center Phase III Study Design and ApprovalThe global multi-center, randomized, double-blind Phase…
-
AstraZeneca Partners with Guangzhou Institute to Advance Respiratory Medicine Research
•
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced a partnership with China’s Guangzhou Institute of Respiratory Health National Center for Respiratory Medicine. The collaboration will focus on enhancing efforts in basic medicine, translational medicine, and clinical medical research. The partnership aims to explore the collection and clinical application of…
-
Indonesia and China Deepen Healthcare Ties with High-Level Dialogue and New Agreements
•
Indonesia’s deputy minister of health, Dante Saksono Harbuwono, visited China last week as part of the third health-focused ‘High-Level Dialogue’ between the two nations. The visit encompassed a bilateral meeting with Harbuwono’s counterpart in the National Health Commission (NHC) of China and the witnessing of a significant cooperation agreement signing…
-
Shanxi Province Begins Historical Procurement Data Collection for Pacemaker VBP Round
•
In preparation for a volume-based procurement (VBP) round, Shanxi province has initiated the gathering of historical procurement data related to pacemakers. This process will involve the participation of all public medical institutions, including military medical institutions, with an option for other medical institutions to join if desired. Reporting of Historic…
-
TYK Medicines Secures FDA Approval for Next-Generation TKI Clinical Trial
•
China-based TYK Medicines, Inc. has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its in-house developed next-generation tyrosine kinase inhibitor (TKI). This marks a significant step forward in the development of the company’s pipeline, with a separate clinical trial filing for…
-
Sequanta Technologies Partners with Element Biosciences to Expand Single-Cell Applications
•
Shanghai-based Sequanta Technologies, a leading multi-omics research and clinical service provider, has announced a strategic partnership with US firm Element Biosciences. With the integration of Element’s sequencing platform, the AVITI system, Sequanta is poised to enhance its focus on single-cell applications. The terms of the financial agreement have not been…
-
Fujian Healthcare Security Bureau Updates Sunshine Procurement Mechanism for Drugs
•
The Fujian Provincial Healthcare Security Bureau has released the Notice on Adjusting and Improving the Sunshine Procurement Mechanism for Drugs, outlining new criteria for drugs to be considered for online procurement. According to the notice, drugs that meet specific requirements and have quotes no higher than the current online prices…
-
Yifan Pharmaceutical Receives NMPA Approval for Hyruan ONE in Knee Osteoarthritis Treatment
•
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced receiving market approval from the National Medical Products Administration (NMPA) for its in-licensed Category 5.1 drug Hyruan ONE (sodium hyaluronate), which is indicated for use in knee osteoarthritis. Hyruan ONE: A Single-Dose Preparation for Knee OsteoarthritisHyruan ONE, originally developed by LG…
-
Junshi Biosciences Challenges Alynlam’s PCSK9 siRNA Patent with CNIPA
•
Junshi Biosciences (SHA: 688180) is reportedly taking steps to challenge a key patent held by Alynlam Pharmaceutical related to the development of PCSK9-targeted small-interfering RNA (siRNA) therapies, such as the lipid-lowering drug Leqvio (inclisiran), which is now marketed globally by Novartis. CNIPA Oral Proceedings and Patent DisputeAccording to a notification…
-
ApolloBio Partners with Baidu Health to Enhance Marketing of IgM Nano Immunoglobulin Spray
•
Guangzhou-based biotech ApolloBio has signed a strategic cooperation agreement with Baidu Health. Under this partnership, Baidu will provide innovative digital support to enhance ApolloBio’s marketing activities, particularly for protective products related to infectious respiratory diseases. This includes an IgM nano immunoglobulin protective spray, known as a ‘liquid mask’ type nasal…
-
China’s Provincial Governments Implement Second Batch of National Drug Use Monitoring Policy
•
In line with a notification issued by the National Health Commission (NHC) in January, provincial governments across China have begun implementing the second batch of drugs under the National Drug Use Monitoring policy. These governments are customizing their drug lists to address local misuse of medicines. On April 3, 2023,…
-
Yantai Dongcheng Pharmaceutical Gets Singapore Regulatory Approval for 177Lu-LNC1004 Phase I Study
•
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving the green light from the regulatory body in Singapore to initiate a Phase I clinical study for its radiotherapeutic drug, 177Lu-LNC1004, which targets fibroblast activation protein (FAP) and is under development to treat FAP-positive advanced solid tumors. This…
-
AcoStream Second-Generation Receives NMPA Marketing Approval for Peripheral Vascular Use
•
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its second-generation AcoStream, a product designed to remove blood clots in the peripheral vascular system. Advancement in Blood Clot Removal TechnologyThe first-generation version of AcoStream was approved for marketing in…
-
Shenzhen Kangtai Biological Partners with Biotis for 13-Valent Pneumococcal Vaccine in Indonesia
•
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has struck a partnership with Indonesian firm Biotis concerning a dual carrier 13-valent pneumococcal polysaccharide conjugate vaccine. This collaboration aims to enhance vaccine accessibility and public health initiatives in Indonesia. Agreement Details and Technical CollaborationAs per the agreement, Kangtai Bio will…
-
Harbour BioMed and AstraZeneca Partner to Advance Pharmaceutical Innovation in Yangtze River Delta
•
Harbour BioMed (HKG: 2142), a biotech with operations in the United States, the Netherlands, and Suzhou (China), has announced a partnership with UK major AstraZeneca (AZ, NASDAQ: AZN). The collaboration aims to advance the construction of a pharmaceutical industry innovation alliance in the Yangtze River Delta region, strengthen global collaboration…
